Humana (NYSE:HUM) Shares Down 2.7%

Humana Inc. (NYSE:HUM)’s stock price dropped 2.7% on Wednesday . The company traded as low as $362.78 and last traded at $364.86. Approximately 289,561 shares changed hands during mid-day trading, a decline of 84% from the average daily volume of 1,805,654 shares. The stock had previously closed at $374.82.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Robert W. Baird began coverage on Humana in a research note on Thursday, May 30th. They set a “neutral” rating and a $374.00 target price for the company. Barclays cut their target price on Humana from $356.00 to $310.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 2nd. Royal Bank of Canada reduced their target price on Humana from $415.00 to $353.00 and set an “outperform” rating for the company in a research note on Thursday, April 25th. Piper Sandler began coverage on shares of Humana in a research note on Wednesday, June 26th. They issued an “overweight” rating and a $392.00 price target for the company. Finally, Argus cut shares of Humana from a “buy” rating to a “hold” rating in a report on Wednesday, March 13th. Fourteen research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $409.55.

Humana Price Performance

The firm has a market capitalization of $43.72 billion, a price-to-earnings ratio of 22.76, a PEG ratio of 2.16 and a beta of 0.51. The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.77. The business has a 50-day moving average price of $345.69 and a two-hundred day moving average price of $350.79.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, topping the consensus estimate of $6.12 by $1.11. The firm had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. The firm’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same period last year, the company earned $9.38 earnings per share. As a group, research analysts forecast that Humana Inc. will post 16.27 EPS for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a $0.885 dividend. The ex-dividend date is Friday, June 28th. This represents a $3.54 annualized dividend and a yield of 0.98%. Humana’s dividend payout ratio is presently 22.04%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Rakuten Securities Inc. bought a new position in Humana during the fourth quarter valued at about $25,000. Gradient Investments LLC grew its stake in shares of Humana by 200.0% in the 4th quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 40 shares during the last quarter. Cetera Trust Company N.A bought a new stake in shares of Humana in the 4th quarter worth approximately $28,000. Private Wealth Management Group LLC acquired a new stake in Humana during the fourth quarter valued at approximately $32,000. Finally, Carolinas Wealth Consulting LLC boosted its holdings in Humana by 274.1% during the fourth quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock worth $46,000 after buying an additional 74 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.